通心络胶囊联合阿托伐他汀治疗冠心病的疗效及其对血清cTnI、cTnT、hs-CRP水平的影响

Therapeutic effect of Tongxinluo capsule combined atorvastatin on coronary heart disease and its influence on serum levels of cTnI, cTnT and hsCRP

目的:研究通心络胶囊联合阿托伐他汀治疗冠心病(CHD)的疗效及其对血清心肌肌钙蛋白I(cTnI)、心肌肌钙蛋白T(cTnT)、高敏C反应蛋白(hsCRP)水平的影响.方法:2018年1~6月于我院治疗的106例CHD患者被随机均分为阿托伐他汀组和联合治疗组(接受阿托伐他汀联合通心络胶囊治疗),两组均治疗14d.观察比较两组治疗前后血清cTnI、cTnT、hsCRP水平及治疗总有效率.结果:联合治疗组总有效率显著高于阿托伐他汀组(90.57%比75.47%),P=0.038.与治疗前比较,治疗后两组血清cTnI、cTnT、hsCRP水平均显著降低,P均=0.001.与阿托伐他汀组比较,联合治疗组治疗后血清cTnI[(0.29±0.06)ng/ml比(0.17±0.03)ng/ml]、cTnT[(0.48±0.10)ng/ml比(0.32±0.06)ng/ml]、hsCRP[(19.89±1.98)ng/ml比(13.16±1.56)ng/ml]水平降低更显著,P均=0.001.结论:通心络胶囊联合阿托伐他汀治疗冠心病患者的疗效显著,可显著降低血清cTnI、cTnT、hsCRP水平.

Objective:To study therapeutic effect of Tongxinluo capsule combined atorvastatin on coronary heart disease(CHD) and its influence on serum levels of cardiac troponin I(cTnI), cardiac troponin T(cTnT) and high sensitive C reactive protein(hsCRP). Methods:A total of 106 CHD patients treated in our hospital from Jan 2018 to Jun 2018 were randomly and equally divided into atorvastatin group and combined treatment group(received Tongxinluo capsule combined atorvastatin). Both groups were treated for 14 d. Serum levels of cTnI, cTnT and hsCRP before and after treatment and total effective rate were observed and compared between two groups. Results:Total effective rate of combined treatment group was significantly higher than that of atorvastatin group(90.57% vs. 75.47%), P=0.038. Compared with before treatment, after treatment, there were significant reductions in serum levels of cTnI, cTnT and hsCRP in two groups, P=0.001 all. Compared with atorvastatin group after treatment, there were significant reductions in serum levels of cTnI [(0.29±0.06)ng/ml vs.(0.17±0.03)ng/ml], cTnT [(0.48±0.10)ng/ml vs.(0.32±0.06)ng/ml] and hsCRP [(19.89±1.98)ng/ml vs.(13.16±1.56)ng/ml] in combined treatment group, P=0.001 all. Conclusion:Tongxinluo capsule combined atorvastatin possesses significant therapeutic effect on CHD patients. It can significantly reduce serum levels of cTnI, cTnT and hsCRP.